| |||||||
|
Edward Abrahams
Executive Director Edward Abrahams, Ph.D., Executive Director of the Personalized Medicine Coalition, a non-profit educational and advocacy group representing diverse members with a interest in advancing medical progress through the adoption of personalized medicine concepts and products, brings extensive experience in industry, academia, and government to the position. As former Executive Director of the Pennsylvania Biotechnology Association, Dr. Abrahams managed all aspects of the Association, including public advocacy, media relations, and educational programs, tripling its size and revenues in three years. He also spearheaded the successful effort that led to the Commonwealth of Pennsylvania's investment of $200 million to commercialize biotechnology in that state. Previously, Dr. Abrahams had been Assistant Vice President for Federal Relations at the University of Pennsylvania, and also held a senior administrative position at Brown University. Before becoming a university administrator, Dr. Abrahams worked seven years for the United States Congress, including as a legislative assistant to Senator Lloyd Bentsen and as an economist for the Joint Economic Committee under the chairmanship of Congressman Lee Hamilton. In addition to articles in both popular and professional journals, he is the author of The Lyrical left: Randolph Bourne, Alfred Stieglitz and the Origins of Cultural Radicalism in America. |
|
|
Joanne Armstrong, M.D., M.P.H.
Joanne Armstrong, MD, MPH is a senior medical director at Aetna where she leads the areas of women's health and genetics. In this role, she is the clinical and strategic lead for genomic medicine-related activities including policy development, clinical program development and implementation, medical cost management efforts, and other activities. Dr. Armstrong is board-certified in obstetrics and gynecology and has additional training in epidemiology and public health. Aetna is the nation's third largest health benefits company, providing medical benefits for nearly 16 million individuals and pharmacy benefits for 10 million individuals. |
|
|
M. Kathleen Behrens, Ph.D. Member, President's Council of Advisors on Science and Technology Dr. Behrens presently serves as a member of the President's Council of Advisors on Science and Technology (PCAST), a role in which she has served since 2001. She was a director of the Board on Science, Technology and Economic Policy (STEP) for the National Research Council from 1997-2005, at which time she also participated as a member of the Institute of Medicine Committee on New Approaches to Early Detection and Diagnosis of Breast Cancer. Kathy was a director of the National Venture Capital Association from 1993 to 2000, also serving as President of the NVCA from May, 1998 through April, 1999, Chairman from May 1999 through September, 1999 and Past Chairman from October 1999 through April, 2000. Dr. Behrens was a Trustee of the University of California, Davis, Foundation from 1996-2001 and also is a member of the Advisory Committee for the J. David Gladstone Institutes. Kathy holds a Ph.D. in Microbiology from the University of California, Davis, where she performed genetic research for six years. Kathy established a career in the financial services industry, working with Robertson Stephens & Co. from 1983 through 1996, at which time the firm was sold. During this tenure, she became a general partner and managing director. Dr. Behrens continued in her capacity as a General Partner for selected venture funds for RS Investments from 1996 through today, after management led a buy-out of that firm from Bank of America. Her professional career included tenures as a public-market biotechnology securities analyst, as well as venture capitalist focusing on healthcare, technology and related investments. She was instrumental in the founding of several biotechnology companies including Protein Design Labs, Inc. and COR Therapeutics, Inc. and participated in financing a broad range of biotechnology, health services and device companies. Most recently, Kathy served as a director of Abgenix, Inc. in a role that spanned that firm's early rounds of private financings through the company's sale in 2006 to Amgen, Inc. |
|
|
Samuel Broder, M.D.
Dr. Samuel Broder joined Celera at its founding in 1998, as the Executive Vice President for Medical Affairs and Chief Medical Officer. Before joining the company, he had been appointed by President Reagan to serve as Director of the National Cancer Institute in 1989, a position he held for six years. His laboratory interests include anti-retroviral therapy, and also, the relationship between immunodeficiency disorders and cancer. His laboratory focused on the role of suppressor cells in various immunodeficiency states and on neoplasms of immunoregulatory T cells. His laboratory was also instrumental in developing several of the first drugs now widely used in the therapy of AIDS and its related disorders in adults and children, especially nucleosides such as Retrovir® (AZT), Videx®(ddI), and HIVID®(ddC). He also oversaw the development of other agents, such as TAXOL®. While serving as NCI Director, he helped launch a number of large-scale clinical trials related to the prevention, diagnosis, and treatment of cancer and inaugurated the SPORE Program. He is the author or co-author of over 330 scientific publications. He has received numerous scientific awards related to his research in cancer and AIDS. His current interests relate to applying knowledge of the human genome, DNA diagnostics, and proteomics to the development of new strategies to treat cancer. |
|
|
Clayton M. Christensen, D.B.A.
Clayton M. Christensen is the Robert and Jane Cizik Professor of Business Administration at the Harvard Business School, with a joint appointment in the Technology & Operations Management and General Management faculty groups. His research and teaching interests center on the management issues related to the development and commercialization of technological and business model innovation. Specific areas of focus include developing organizational capabilities and finding new markets for new technologies. Professor Christensen holds a B.A. with highest honors in economics from Brigham Young University (1975), and an M.Phil. in applied econometrics and the economics of less-developed countries from Oxford University (1977), where he studied as a Rhodes Scholar. He received an MBA with High Distinction from the Harvard Business School in 1979, graduating as a George F. Baker Scholar. He was awarded his DBA from the Harvard Business School in 1992. Clayton M. Christensen is the Robert and Jane Cizik Professor of Business Administration at the Harvard Business School, with a joint appointment in the Technology & Operations Management and General Management faculty groups. His research and teaching interests center on the management issues related to the development and commercialization of technological and business model innovation. Specific areas of focus include developing organizational capabilities and finding new markets for new technologies. |
|
|
Nadine Cohen, Ph.D.
Nadine Cohen was trained as a pharmacist in France and received her Ph.D. in Immunogenetics in 1986 from the Hebrew University in Jerusalem. She was a post-doctorate fellow at Stanford University until 1989, and after heading the genetic screening laboratory at the Foundation Jean Dausset-Human Polymorphism Study Center in Paris, she was an Assistant Professor from 1995-2001 at the Technion Bruce Rappaport Faculty of Medicine in Haifa (Israel). She joined the Jansen Research Foundation in August 1999 to establish a Pharmacogenomics program. She is currently Head of the Pharmacogenomics Team at the Johnson and Johnson Pharmaceutical Research and Development (Raritan, NJ, USA). She has published more than 60 scientific papers in the area of immunogenetics and human molecular genetics. Nadine Cohen is also the current elected chair of the industry Pharmacogenetics Working Group, and represents Johnson and Johnson on various external organizations engaged in Pharmacogenomics and Personalized Medicine. |
|
|
Mason Freeman, M.D.
Mason Freeman, MD is Chief of the Lipid Metabolism Unit at Massachusetts General Hospital, Harvard Medical School. Trained in internal medicine and endocrinology, Dr. Freeman has spent the past twenty years studying the trafficking of cholesterol into and out of macrophages. He founded and still directs the Lipid Clinic at MGH and is an internationally recognized expert in the treatment of lipid disorders. In 2005, Dr. Freeman took a sabbatical from Harvard to work as Vice-President and Global Head of Translational Medicine for Cardiovascular, Diabetes, and Metabolic Diseases at the Novartis Institutes of Biomedical Research in Cambridge, MA. In this role, he and his translational medicine team were responsible for designing the early development programs for drugs affecting hypertension, diabetes, obesity, atherosclerosis and lipid disorders. On returning to MGH in 2007, he assumed the dual roles of Director of the Genetics Enters Medicine trials in Partners and Director of Translational Medicine at MGH. Dr. Freeman received his A.B from Harvard College, M.D. from the University of California, San Francisco, and did post-doctoral training in cell biology and lipid metabolism at MIT. |
|
|
Felix W Frueh, Ph.D.
Dr. Frueh holds the position of Associate Director for Genomics in the Office of Clinical Pharmacology (OCP) in the Center for Drug Evaluation and Research (CDER) at the FDA and also chairs the FDA-wide Interdisciplinary Pharmacogenomics Review Group (IPRG). Prior to his appointment at the FDA, Dr. Frueh was Managing Partner at Stepoutside Consulting, LLC, and served as a Special Government Employee to the FDA and as a consultant to the CDC's NHANES project. He held the position of Research Director for Pharmacogenetics at Transgenomic, Inc., managing the expansion of the business into new program areas for the diagnosis of genetic disorders. Prior, Dr. Frueh was the Assistant Director for Biology at Protogene Laboratories, Inc., responsible for application development based on novel, in situ synthesized DNA microarray technology. He held an appointment as Assistant Professor at Georgetown University, Washington, DC in the Departments of Pharmacology and Medicine and was a postdoctoral fellow at Stanford University and at the Biocenter of the University of Basel, Switzerland. Felix is a native of Basel and lives in Maryland with his wife and two sons. |
|
|
John Glaser, Ph.D.
John Glaser, PhD, is Vice-President and Chief Information Officer, Partners HealthCare System, Inc. Previously, he was Vice-President, Information Systems at Brigham and Women's Hospital. Prior to Brigham and Women's Hospital, Dr. Glaser managed the Healthcare Information Systems consulting practice at Arthur D. Little. Dr. Glaser was the founding Chairman of College of Healthcare Information Management Executives (CHIME) and is past President of the Healthcare Information and Management Systems Society (HIMSS). He has been a member of the Board of the American Medical Informatics Association. Dr. Glaser is currently the Chairman of the eHealth Initiative Board and the Senior Advisor for National HIT Adoption for CHIME. He is a Senior Advisor to the Deloitte Center for Health Solutions. He is a fellow of HIMSS, CHIME and the American College of Medical Informatics. He has been awarded the John Gall award for healthcare CIO of the year. CHIME has established a scholarship in Dr. Glaser's name. He was a recipient of CIO Magazine's 20/20 Vision Award. Partners HealthCare has received several industry awards for its effective and innovative use of information technology. Dr. Glaser has published over one hundred articles and four books on the strategic application of information technology in healthcare. He holds a Ph.D. in Healthcare Information Systems from the University of Minnesota. |
|
|
Richard G. Hamermesh, D.B.A.
Richard Hamermesh is the MBA Class of 1961 Professor of Management Practice at the Harvard Business School where he teaches in the MBA Program and is the Faculty Chair of the HBS Healthcare Initiative. Richard created and teaches the second-year MBA elective, Entrepreneurship and Venture Capital in Healthcare. Previously, he was the Course Head for the required first year course entitled The Entrepreneurial Manager. From 1987 to 2001, Richard was a co-founder and a Managing Partner of The Center for Executive Development, an executive education and development consulting firm. Prior to this, from 1976 to 1987, he was a member of the faculty of the Harvard Business School. Richard is also an active investor and entrepreneur, having participated as a principal, director, and investor in the founding and early stages of over 20 organizations. These have included start-ups, leveraged buy-outs, industry roll-ups, and non-profit foundations. He was the founding president of the Newton (MA) Schools Foundation and served on the editorial board of the Harvard Business Review. He is currently on the Boards of one public and two private corporations, as well as two non-profit Boards. From 1991 to 1996, he was the founding Chairman of Synthes Spine, Inc. Richard is the author or co-author of five books, including New Business Ventures and the Entrepreneur. His best-known book, Fad-Free Management, was published in 1996. He has published numerous articles and more than 100 case studies. His most recent article, "Realizing the Potential of Personalized Medicine," will appear in the Harvard Business Review (October 2007). Richard received his AB from the University of California, and his MBA and DBA from HBS. He is married, has two children, and his hobbies include tennis, skiing, and yoga. |
|
|
Dora L. Hughes, M.D., M.P.H.
Dr. Dora Hughes advises Senator Barack Obama on a broad range of health issues and helps to develop his national policy and legislative agenda. She previously served as Deputy Director for Health for Senator Edward M. Kennedy on the Committee on Health, Education, Labor and Pensions in the United States Senate. Prior to working on Capitol Hill, Dr. Hughes served as Senior Program Officer at The Commonwealth Fund, a national health foundation in New York City. She completed medical school at Vanderbilt University, residency at Brigham & Women's Hospital and public health school at Harvard University. Dr. Hughes is board-certified in internal medicine. |
|
|
Michael O. Leavitt
Michael O. Leavitt was sworn in as the 20th Secretary of the U.S. Department of Health and Human Services on January 26, 2005. As secretary, he leads the Nation's efforts to protect the health of all Americans and provide essential human services to those in need. He manages one of the largest civilian departments in the federal government, with a budget that accounts for almost one out of every four federal dollars and more than 67,000 employees. During his first year, he led efforts to successfully enroll tens of millions of seniors and disabled persons in the new Medicare prescription drug benefit; mobilized the nation's pandemic preparedness; accelerated the development of health information standards and oversaw the medical response to Hurricane Katrina. He also presided over changes in Medicaid statutes to give states flexibility to provide targeted insurance coverage to more people, and reauthorization by Congress, after ten extensions, of the Temporary Assistance to Needy Families. He is intensively focused on making health care more transparent in quality and price, and reducing the time and expense of bringing safe and effective drugs to market. Prior to his current service, Leavitt served as head of the U.S. Environmental Protection Agency and three-term Governor of Utah. During his eleven years of service, Utah was recognized six times as one of America's best managed states. He was chosen by his peers as Chairman of the National Governors Association, Western Governors Association and Republican Governors. Prior to his public service, he served as president and chief executive officer of a regional insurance firm, establishing it as one of the top insurance brokers in America. He is married to Jacalyn S. Leavitt; they are the parents of five children. |
|
|
John C. Lechleiter, Ph.D.
John C. Lechleiter, Ph.D., was named president and chief operating officer in October 2005. He previously served as executive vice president, pharmaceutical operations since January 2004. He had been executive vice president for pharmaceutical products and corporate development since 2001. Lechleiter is a member of the company's policy and strategy committee, and also chairs the company's operations committee. Lechleiter received a bachelor of science degree summa cum laude in chemistry from Xavier University (Cincinnati, Ohio) in 1975. He studied organic chemistry as a National Science Foundation Fellow at Harvard University, where he received his master's and doctorate degrees in 1980. In 2006, Lechleiter received an honorary doctorate of business administration from Marian College of Indianapolis. Joining Lilly in 1979 as a senior organic chemist in process research and development, Lechleiter became head of that department in 1982. In 1983, he began serving as director of pharmaceutical product development for the Lilly Research Center Limited, in Windlesham, England. He returned to the United States in 1986 as manager of research and development projects for Europe. In 1988, he became director of development projects management and subsequently assumed additional responsibility for pharmaceutical regulatory affairs: chemistry, manufacturing, and control in 1989. In 1991, he was named executive director of pharmaceutical product development and became vice president in 1993. He was appointed vice president of regulatory affairs in 1994. In 1996, he was named vice president of Lilly Research Laboratories, a division of Eli Lilly and Company, responsible for development and regulatory affairs. Lechleiter became senior vice president, pharmaceutical products in 1998. Lechleiter is a member of the American Chemical Society. In 2004, he was appointed to the Visiting Committee of Harvard Business School and to the Health Policy and Management Council of the Harvard School of Public Health. He also serves as a member of the Board of Trustees of Xavier University in Cincinnati. In addition, he serves as a distinguished advisor of The Children's Museum of Indianapolis, a member of the Dean's Advisory Council at the Indiana University School of Medicine, a member of the Board of Directors and Executive Committee of Fairbanks Institute, and a member of the United Way of Central Indiana Board of Directors. |
|
|
Jeffrey D. Miller
As Vice President, Worldwide Health and Life Sciences (HLS), Jeff Miller is responsible for market strategy, business planning, service offerings, and solutions development for the healthcare provider, health insurer, pharmaceutical/biotech, and life sciences research market segments. He oversees the marketing and sales activities for this industry sector, driving overall effectiveness and impact on a global scale. In addition, Miller has responsibility for strategic oversight of HP's global sales and services efforts in the Public Sector. For several years, Miller has focused his activities on enabling the transformation of the HLS industry as it has evolved from departmental technology solutions into an ecosystem with an integrated set of solutions that allow participants across the value chain to digitize content, analyze data, and manage their information collaboratively and effectively, and where the quality of patient care is critical to sustainable competitive advantage. During his tenure, industry analysts report that HP HLS revenues have grown to more than $5 billion annually. Miller has more than twenty years experience in strategic planning, product development, and operational process improvement in the health care, manufacturing, public sector, and technology industries. Prior to joining HP, he led the development and delivery of management consulting services at The Advisory Board Company and Deloitte Consulting. He has worked with a diverse set of Health industry organizations on the identification and development of transformational strategies and the implementation of technology-enabled business processes. Previously, he managed a variety of business strategy, product planning, and development operations organizations at IBM. Miller is based in Research Triangle Park, North Carolina. He holds a master's of Business Administration from the Fuqua School of Business at Duke University in Durham, North Carolina, and a bachelor’s in Economics from Northwestern University in Chicago. |
|
|
Thomas Miller
Member of the executive board of Siemens Medical Solutions (Med) in Erlangen Miller holds an impressive professional track record within Siemens and other multinational corporations. During his initial 15-year tenure with Siemens, Miller headed up Med's Magnetic Resonance (MR) product division, and the U.S. sales and service organization. Afterwards Miller was vice president, Business Development, for Siemens Medical Solutions in Erlangen, Germany. Most recently, he led the Siemens Medical Solutions Health Services Corporation (HS). Miller will tell you that there isn't a lack of information in the healthcare industry, but rather, it's perfecting the management of that information that will help healthcare organizations become more efficient and positively impact patient outcomes. His mission is to achieve the goals of assuring patient safety, increasing operational efficiency and improving clinical outcomes for all of Siemens' IT customers. Doing this means moving information through the healthcare continuum in an effective and meaningful way, analyzing and using it to continuously improve the processes involved in today's standards of care, resulting in true workflow optimization, expanding beyond the automation of manual processes. In addition to his leadership positions at Siemens, Miller also was president and CEO of Carl Zeiss, Inc., the American subsidiary of the optical company, and simultaneously the general manager of their worldwide medical division, responsible for surgical microscopes and ophthalmology products. Tom also served as president and CEO of Analogic Corporation, a manufacturer of components and subsystems for the healthcare and security industry. He also co-founded a company, LightLab Imaging, to commercialize a new diagnostic-imaging method called optical coherence tomography (OCT), which enables the acquisition and display of real-time ultra high-resolution, cross-sectional images with light. During the summer of 2002, following successful initial clinical trials for vulnerable plaque imaging in coronary arteries, he sold the operation to a Japanese company. Whether he is racing motorcycles, bicycling, reading a classic or listening to music, the one thing that remains constant is Miller's passion for life. This exuberance is also true in is his commitment to his work. As Miller sees it, the potential for healthcare IT is boundless and the exponentially increasing pace of technological advances offer great possibilities to those who can leverage it. Miller holds a B.S. in nuclear engineering with a minor in English literature from the University of Massachusetts and a master’s degree from Harvard Medical School/MIT's joint program in medical physics. |
|
|
Anthony Miller
Tony Miller co-founded Lemhi Ventures in 2006 to build the capital base and value added approach of forming and helping companies continue to advance the marketization of the healthcare industry. Additionally, Mr. Miller is part of the leadership team at Carol Corporation, a Lemhi Ventures Portfolio company. Mr. Miller serves on the Boards of VisionShare, and Carol Corporation. Prior to founding Lemhi Ventures, Mr. Miller was a co-founder and CEO of Definity Health, a national market leader in consumer-driven health benefit programs, which was sold to UnitedHealth Group in 2004. Mr. Miller regularly serves as an industry expert in articles and other news coverage and is a frequent speaker on the topics of consumer-driven healthcare and health policy. Prior to founding Definity Health, Mr. Miller was a consultant at Deloitte Consulting where he focused on strategic business development in the managed care industry, including mergers and acquisition, market development and performance turnarounds. Mr. Miller holds an M.B.A. from Cornell University's Johnson Graduate School of Management and an M.S. in Kinesiology from the University of Illinois at Champaign-Urbana. |
|
|
Garry Neil, M.D.
Garry Neil, M.D. is Corporate Vice President, Corporate Office of Science & Technology (COSAT), Johnson & Johnson. In this role, Garry leads a team that catalyzes sustained cross-sector growth for Johnson & Johnson by identifying and launching emerging technologies that underpin the creation of future businesses. He has broad experience in the science, medicine and pharmaceutical research and development. He has held a number of senior positions within J&J, most recently Group President, Johnson and Johnson Pharmaceutical Research and Development. Under his leadership a number of important new medicines for the treatment of cancer, anemia, infections, central nervous system and psychiatric disorders, pain, and genitourinary and gastrointestinal diseases, gained initial or new and/or expanded indication approvals. Garry joined J&J in 2002. He previously held senior-level positions with Astra Merck Inc., Astra Pharmaceuticals, Astra Zeneca and Merck KGaA. He has also held a number of academic posts at a number of academic institutes including the Ludwig Institute for Cancer Research, the University of Toronto, the University of Iowa College of Medicine and the University of Pennsylvania (adjunct). He has written more than 50 articles and book chapters. He is a Fellow of the American College of Physicians, a Fellow of the American College of Gastroenterology, a member of the American Association of Immunologists, and the Society for Clinical Trials. He is a member of the Board of the J&J Development Corporation and is J&J's representative to, and Vice Chairman, of the Pharmaceutical Research and Manufacturers Association (PhRMA) Science and Regulatory Committee, Vice Chairman and Treasurer of the PhRMA Foundation Board, a member of the Board of Trustees for the University of Medicine and Dentistry of New Jersey, a member of the Executive Committee of the Biomarkers Consortium, and a member of the Board of Trustees of the Newark Boys Chorus School. |
|
|
Samuel Nussbaum, M.D.
Dr. Samuel Nussbaum is executive vice president and chief medical officer for WellPoint, Inc. He oversees corporate medical policy, clinical pharmacy programs, health improvement and quality resources, programs for clinical excellence, disease and care management, and clinical informatics to optimize care for members. Dr. Nussbaum also has responsibility for the Health Management Corporation (HMC) and HealthCore subsidiaries. When Anthem, Inc. merged with WellPoint Health Networks Inc. in November 2004 and was subsequently renamed WellPoint, Inc., Dr. Nussbaum was serving as executive vice president and chief medical officer of Anthem. He joined Anthem in January 2001. His principal responsibilities continue to include: serving as chief spokesperson on medical issues, guiding the corporate vision regarding quality of care and its measurements, leading efforts to assess cost of care performance and developing a strategy to foster further collaboration with physicians and hospitals to strengthen and improve patient care. Dr. Nussbaum has served as president of the Disease Management Association of America, Chairman of the National Committee for Quality Health Care, as Chair of America's Health Insurance Plan's (AHIP) Chief Medical Officer Leadership Council and as a member of the AHIP Board. He received the 2004 Physician Executive Award of Excellence from the American College of Physician Executives and Modern Physician magazine. Dr. Nussbaum is a member of numerous professional organizations and has spoken at national and regional conferences pertaining to his medical research as well as on health-care delivery. Dr. Nussbaum is professor of clinical medicine at Washington University School of Medicine and serves as adjunct professor at the Olin School of Business, Washington University. Dr. Nussbaum served as executive vice president, Medical Affairs and System Integration, of the BJC Health System-one of the largest academic and community integrated health and hospital systems in the United States, where he also served as CEO of its health plan and president of its medical group. Dr. Nussbaum earned his medical degree from Mount Sinai School of Medicine. He trained in internal medicine at Stanford and Harvard and in endocrinology and metabolism at Harvard and Massachusetts General Hospital, where he directed the Endocrine Clinical Group and the Musculoskeletal Pathophysiology course at Harvard Medical School. His clinical and basic research has led to new therapies to treat skeletal disorders and new technologies to measure hormones in blood. Nussbaum is board-certified in internal medicine and specialty certified in endocrinology and metabolism. |
|
|
Wayne A. Rosenkrans, Jr., Ph.D.
Wayne is Director of External Relations for the Personalized Healthcare Team at AstraZeneca and for Evidence-based Medicine (EBM) as part of External Medical Relations where he has responsibility for long-range external relations strategy and policy development. He is Chairman, President and a member of the board of directors of the Personalized Medicine Coalition, a Washington DC based organization working with government and other agencies on evolving healthcare policy for Personalized Healthcare. He also is involved in a number of workstreams at the Institute of Medicine (IOM), and represents AZ on several strategy and advisory boards at different organizations including the Health Industry Forum, National Pharmaceutical Council, C-Path Institute, MIT, Georgetown University, IBM, and the Personalized Healthcare Initiative in the Secretary's office at Health and Human Services. He has presented at numerous forums on aspects of personalized healthcare, evidence-based medicine, new development paradigms, and strategy development. He holds an S.B. in Biology from MIT, a Ph.D. in Cell and Molecular Biology from Boston Univ., and received post-doctoral training in Cancer and Radiation Biology at the Univ. of Rochester. Wayne is based in Wilmington, is married with two college-age children, and enjoys teaching martial arts (Tang Soo Do), restoring antique/classic Fords, and aviation history. |
|
|
Hakan Sakul, Ph.D.
Since May 2007 Hakan has been a Senior Director in the Translational and Molecular Medicine Group where he is the Global Head of Diagnostics, leading Pfizer's Diagnostics effort across all therapeutic areas. Hakan joined Parke-Davis in December 1998 as Director of Human Genetics, Statistical Genetics and Pharmacogenetics programs. Due to site closure shortly after Pfizer's merger with Warner-Lambert, he moved to Ardais Corporation in Lexington, MA as Vice President of Statistical Genomics, after which he returned to Pfizer in November 2001 as Director and Site Head for Clinical Pharmacogenomics in Groton/New London Laboratories. Hakan was promoted to Senior Director in mid-2005 and was responsible for programs in CNS and Infectious Diseases prior to assuming his current role. Hakan is a native of Turkey where he completed his BS and MS degrees. He then completed his PhD degree in Quantitative Genetics at the University of Minnesota as a Rotary Foundation Scholar. He completed a postdoctoral program at the University of California, Davis in quantitative genetics, animal genetics and international agriculture before moving into the biotech industry in human genetics and pharmacogenomics in 1995. Hakan has authored over 30 scientific refereed articles, several book chapters, and served as invited speaker on many panels and scientific meetings. He represents Pfizer on the Clinical Science and Technology Committee of Personalized Medicine Coalition, and Pharmacogenetics Working Group. Hakan is keenly interested in applications of diagnostics, pharmacogenomics and other -omics to the pharmaceutical pipeline as a business enabler, and their applications in improving and individualizing patient care. |
|
|
Peer M. Schatz
Peer M. Schatz is QIAGEN's Chief Executive Officer and Chairman of the Executive Committee. He joined QIAGEN in 1993 as Chief Financial Officer. Mr. Schatz was previously a partner in a private management buyout group in Switzerland and worked in finance and systems positions in Sandoz, Ltd. and Computerland AG as well as in finance, operations, management and sales positions in various start-up companies in the computer and software trading industry in Europe and the United States. Mr. Schatz graduated from the University of St. Gall, Switzerland, with a Master's degree in Finance in 1989 and obtained an M.B.A. in Finance from the University of Chicago Graduate School of Business in 1991. Mr. Schatz is a member of the German Corporate Governance Commission. |
|
|
Ralph Snyderman M.D.
Dr. Snyderman is Chancellor Emeritus, Duke University and James B. Duke Professor of Medicine in the Duke University School of Medicine. He served as Chancellor for Health Affairs and Dean of the School of Medicine from 1989 to July 2004. Dr. Snyderman led the transition of this excellent medical center into an internationally recognized leader of academic medicine. During his tenure, the medical school and hospital achieved ranking amongst the nation's best. Dr. Snyderman oversaw the development of the Duke University Health System, one of the most successful integrated academic health systems in the country, and served as its first President and Chief Executive Officer. Dr. Snyderman has played a leading role in the conception and development of Prospective Care, a novel approach to personalized health and an evolving model of national health care delivery. In 2004, after stepping down as Chancellor, Dr. Snyderman founded Proventys, Inc., a company at the forefront of transforming health care into a personalized and preventative approach through the development of high powered risk assessment and clinical decision support tools. Dr. Snyderman accepted his first faculty appointment at Duke in 1972 and became chief of the Division of Rheumatology and Immunology in 1975 and, by 1984, he was the Frederic M. Hanes Professor of Medicine and Immunology. His research contributed to the understanding of how white blood cells respond to chemical signals to mediate host defense or tissue damage. Dr. Snyderman is internationally recognized for his contributions in inflammation research. His bibliography exceeds 350 manuscripts as well as numerous books. In 1987, Snyderman left Duke to join Genentech, Inc., the pioneering biomedical technology firm, as Senior Vice President for medical research and development and a member of its senior leadership team. While at Genentech, he led the development and licensing of several novel therapeutics. A graduate of Washington College in Chestertown, Md. (1961), Snyderman received his M.D., magna cum laude, in 1965 from the Downstate Medical Center of the State University of New York. He served his internship and residency in medicine at Duke and later worked as a Public Health Officer doing research in immunology at the NIH (1967-72). He is the recipient of numerous honors, including the CIBA GEIGY Award in 1992, the highest prize in inflammation research, the 1993 Bonazinga Award for Excellence in Leukocyte Biology Research and awarded the American College of Rheumatology Master designation in 2005. Snyderman was honored with the Lifetime Achievement Award from the Arthritis Foundation in 1997. In 1995, Downstate Medical Center of the State University of New York awarded him with their Distinguished Alumni Achievement Award, and in 1996, an Honorary Doctor of Science degree. He was the recipient of the Washington College Distinguished Alumni Citation in 1996 and an Honorary Doctor of Science degree in 2004. In November 2003, he was awarded the first Bravewell Leadership Award for outstanding achievements in the field of integrative medicine. Dr. Snyderman has been called upon by Congress, the Institute of Medicine, the NIH, and national policy makers to contribute to the debate on health care reform, particularly his concepts concerning prospective care. He has played a prominent role in the leadership of such important national organizations as the Association of American Physicians, the Institute of Medicine and the Association of American Medical Colleges. He is a member of the Institute of Medicine and the American Academy of Arts & Sciences. He served as Chair of the AAMC in 2001-2002 and President of the Association of American Physicians in 2003-2004. |
|
|
Christine Seidman, M.D.
Christine (Kricket) Seidman is a Professor in the Departments of Medicine and Genetics at Harvard Medical School and Brigham and Women's Hospital. In 2005 she was named the Thomas W. Smith Professor of Medicine. She is also an Investigator of the Howard Hughes Medical Institute. She was an undergraduate at Harvard College and received a M.D. from George Washington University School of Medicine in 1978. Dr. Seidman served as an intern and resident in Internal Medicine at John Hopkins Hospital and received subspecialty training in cardiology at the Massachusetts General Hospital. She joined the staff at Brigham and Women's Hospital in 1987 and is currently the Director of the Cardiovascular Genetics Center. Honors include: Marion Hypertension Research Award (1984); American Heart Association Clinician-Scientist Award (1986); Bristol-Myers Squibb Unrestricted Cardiovascular Research Grant Award (1990); American Heart Association Established Investigatorship Award (1992); Robert J. and Claire Pasarow Foundation Award in Cardiovascular Research (1992); American Heart Association, Edgar Haber Cardiovascular Award (1997); American Heart Association, Helen B. Taussig Memorial Lecturer (1997); Member, Johns Hopkins University Society of Scholars (1998); Member, American Academy of Arts and Sciences (1999); Member, Institutes of Medicine (1999); American Heart Association, Basic Research Prize (1999); Gill Heart Institute Award for Cardiovascular Research (2000); American College of Cardiology, Louis F. Bishop Lecture (2000); Gill Heart Institute Award for Cardiovascular Research (2001); 12th Annual Bristol-Myers Squibb Award for Distinguished Achievement in Cardiovascular Research (joint recipient with Jonathan Seidman, PhD) (2002); Fellow, International Society Heart Research (2002); Distinguished Scientist, American Heart Association (2003); Cannon Award, American Physiologic Society (2004); Member, Association of University Cardiologists (2005); Distinguished Alumni Achievement Award, The George Washington University (2005); Member, National Academy of Sciences (2005); Lefoulon-Delalande Foundation, Grand Prix for Science (joint recipient with Jonathan Seidman, PhD)(2007). |
|
|
Sharon Terry, Ph.D.
Sharon is President and CEO of the Genetic Alliance, a coalition of over 600 disease specific advocacy organizations working to increase capacity in advocacy organizations and to leverage the voices of the millions of individuals and families affected by genetic conditions. She is the founding Executive Director of PXE International, a research advocacy organization for the genetic condition pseudoxanthoma elasticum (PXE). Following the diagnosis of their two children with pseudoxanthoma elasticum (PXE) in 1994, Sharon, a former college chaplain, and her husband, Patrick, founded and built a dynamic organization that fosters ethical research and policies and provides support and information to members and the public. She is at the forefront of consumer participation in genetics research, services and policy and serves as a member of many of the major governmental advisory committees on medical research, including the Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory Committee and the Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children. She served as an Ethical Legal and Social Implications Research Advisor of NHGRI/NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases Council and currently is liaison to the National Advisory Council for Human Genome Research. She is a member of the board of directors of the Biotechnology Institute and on the advisory board of the Johns Hopkins Genetics and Public Policy Center funded by the Pew Charitable Trusts. She serves on the boards of the Coalition for 21st Century Medicine, the Personalized Medicine Coalition, DNA Direct, and the Center for Information and Study on Clinical Research Participation. She is the chair of the Coalition for Genetic Fairness, composed of advocates, healthcare providers and industry working to enact effective federal policy to prohibit genetic information discrimination. She is also chair of the Social Issues Committee of American Society of Human Genetics. In 2005, she received an honorary doctorate from IonaCollege for her work in community engagement and haplotype mapping. Ms. Terry is a co-founder of the Genetic Alliance Biobank and serves as president of its board. It is a centralized biological and data [consent/clinical/environmental] repository catalyzing translational genomic research on rare genetic diseases. The BioBank works in partnership with academic and industrial collaborators to develop novel diagnostics and therapeutics to better understand and treat these diseases. Along with the other co-inventors of the gene associated with PXE (ABCC6), she holds the patent for the invention. She co-directs a 19-lab research consortium and manages 52 offices worldwide for PXE International. Sharon feels strongly that advocates, working together and partnering with professionals and industry, can generate the energy and mechanisms necessary to realize the promise of biomedical research. Her work with the Genetic Alliance over the past few years has particularly focused on genetic literacy, research protections, biosample repositories, technology translation, genetic nondiscrimination, accessible services and youth issues. She has published widely on these issues. Sharon is committed to facilitating technical assistance to advocacy organizations, so that each organization benefits from the wisdom of the other. Sharon lives with Patrick and their two children in Maryland. |
|
Please send your comments or questions
regarding this website to web master.